- Drug Pipelines
- April 2025
- 40 Pages
Global
From €1120EUR$1,250USD£959GBP
- Report
- July 2024
- 100 Pages
Global
From €3360EUR$3,750USD£2,878GBP
- Report
- April 2024
- 143 Pages
Global
From €7123EUR$7,950USD£6,102GBP
- Report
- February 2024
- 245 Pages
Global
From €7123EUR$7,950USD£6,102GBP
- Report
- November 2023
- 630 Pages
Global
From €8512EUR$9,500USD£7,291GBP
- Report
- April 2023
- 110 Pages
Global
From €4256EUR$4,750USD£3,646GBP
- Report
- April 2023
- 119 Pages
Global
From €4256EUR$4,750USD£3,646GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1344EUR$1,500USD£1,151GBP
- Report
- August 2024
- 265 Pages
Global
From €7123EUR$7,950USD£6,102GBP
- Report
- June 2025
- 400 Pages
Global
From €4434EUR$4,949USD£3,798GBP
- Report
- June 2025
- 400 Pages
Global
From €4434EUR$4,949USD£3,798GBP
- Report
- June 2025
- 400 Pages
Global
From €4434EUR$4,949USD£3,798GBP
- Report
- June 2025
- 400 Pages
Global
From €4434EUR$4,949USD£3,798GBP
- Report
- June 2025
- 400 Pages
Global
From €4434EUR$4,949USD£3,798GBP
- Report
- January 2025
- 250 Pages
Global
From €4479EUR$4,999USD£3,837GBP
- Report
- January 2025
- 250 Pages
Global
From €4479EUR$4,999USD£3,837GBP
- Report
- January 2025
- 250 Pages
Global
From €4479EUR$4,999USD£3,837GBP
- Report
- August 2024
- 150 Pages
Global
From €2499EUR$2,789USD£2,141GBP
- Report
- July 2023
- 140 Pages
Global
From €4434EUR$4,949USD£3,798GBP
- Report
- April 2023
- 147 Pages
Global
From €4434EUR$4,949USD£3,798GBP

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more